Flightpath Biosciences and the Forsyth Institute Enter Into Co-Development Agreement Targeting Oral Disease
Flightpath Biosciences, Inc. announced today that it has signed a landmark development agreement with the Forsyth Institute, a globally recognized leader in the fields of...
Core One’s Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson’s Disease
VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU), (the "Company" or "Core One") is delighted to...
Dr. Eric Grigsby Collaborates on Groundbreaking Study of Donanemab’s Impact on Alzheimer’s Disease
Neurovations Research proud to be a part of study that released first positive results to slow Alzheimer's Disease Neurovations, a leading medical research and innovation...